



ASX Announcement

16 April 2026

Share Purchase Plan Offer Opens

SYDNEY Australia, 16 April 2026 – Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) confirms that the Atomo Share Purchase Plan (SPP Offer) opens today.

Attached is copy of the SPP Offer Letter sent to each holder of fully paid ordinary shares who, as at the record date of 7.00pm (AEDT) on Friday, 27 March 2026 had a registered address in Australia and New Zealand (and who otherwise meet certain other conditions as set out in the Prospectus) (Eligible Shareholder).

A copy of the Prospectus and Target Market Determination is available for download at <https://investors.atomodiagnostics.com/spp-2026-prospectus>. Eligible Shareholders who have provided an email address will be sent an email communication. Eligible Shareholders who have not provided an email address will be sent an SPP Offer Letter via post. The SPP Offer is expected to close at 5.00 pm (AEST) on Friday, 8 May 2026 (unless extended, withdrawn or closed early by the Company).

~ ENDS ~

For more information, please contact:

John Kelly

Managing Director & CEO

e. john.kelly@atomodiagnostics.com

p. +61 401 922 279

This announcement was authorised by the Managing Director & CEO.

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of test products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, Active Syphilis, Liver function, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnostics.com



16 April 2026

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO US PERSONS

Dear Shareholder

Atomo Diagnostics Limited Share Purchase Plan

I am pleased to invite you to participate in the offer of fully paid ordinary shares (**Shares**) in Atomo Diagnostics Limited ACN 142 925 684 (**Atomo, ATI or Company**) under the share purchase plan established by Atomo (**Offer or Plan**).

On 30 March 2026, Atomo announced it was undertaking a capital raising to raise up to \$4.0 million, by way of a placement to raise \$3.0 million (**Placement**) and a Share Purchase Plan (**SPP**) to raise up to \$1.0 million (together known as **Capital Raising**). The SPP Offer is not underwritten, but the Company reserves the right to increase the maximum based on overall applications received. In addition, participants will receive one free attaching option (**Option**) for every two Shares subscribed. The Options are to be unlisted and each Option is to have a nil issue price, an exercise price of \$0.045, and an expiry date of 2.5 years from their date of issue.

Details of the Offer and how to participate can be found in the Prospectus (**Prospectus**) and the Target Market Determination (**TMD**) available on the Company's website <https://investors.atomodiagnostics.com/announcements>. Copies of the Prospectus and TMD have also been released to the ASX.

Overview of the Offer

The SPP Offer provides you, as an Eligible Shareholder of Atomo (subject to certain conditions), with the opportunity to acquire a minimum of \$1,000 and up to, in aggregate, \$30,000 of Shares in Atomo at an issue price of \$0.033 per Share (**Issue Price**) free from any brokerage or transaction costs. The Issue Price is the same as the issue price applicable to the Placement to institutional and sophisticated investors.

The Issue Price represents a ~10% discount to the 15-day VWAP of \$0.0368 at the time of announcing the SPP.

Atomo is seeking to raise a maximum of \$1.0 million under the SPP Offer. The Directors have reserved the right to increase this maximum by accepting oversubscriptions under the Plan.

Similarly, the Company reserves the right to either increase the maximum or scale back applications in its sole and absolute discretion. If applications are scaled back, excess funds will be returned to applicants without interest.

Participation in the SPP Offer is optional and is open to Eligible Shareholders who, as at the Record Date, being 7:00 pm AEDT on Friday, 27 March 2026 (**Record Date**), were registered as holders of fully paid ordinary shares in Atomo and whose address on the share register is in Australia or New Zealand.

If an Eligible Shareholder holds shares as a Custodian the SPP Offer is also being made to the Custodian and, subject to certain conditions, the Custodian has the discretion to extend the SPP Offer to the relevant beneficiaries.

Eligible Shareholders may apply for a parcel of new Shares under the Plan valued at \$1,000, \$2,500, \$5,000, \$7,500, \$10,000, \$15,000, \$20,000, \$25,000 or \$30,000. Depending on demand, Atomo may scale back applications or (to the extent permitted by the ASX Listing Rules) raise a higher amount, at its absolute discretion.

Use of Funds

The Offer use of funds for the Capital Raising is to expand commercialisation of Atomo's own portfolio of proprietary diagnostic tests, including Active Syphilis and Liver function, deliver operational scale up to support increased demand for supply of Pascal cassettes for Lumos' FebriDx growth in the US and working capital alongside costs of the Capital Raising.

Timing

The SPP Offer will be undertaken in accordance with the timetable below. However, Atomo reserves the right to vary the dates and times set out below in its complete discretion, subject to the Corporations Act and other applicable laws.

Event	Date
Record Date (the business day prior to Atomo's announcement of the Plan)	7:00 pm AEDT on Friday, 27 March 2026
Capital Raising announced and trading halt lifted	Monday, 30 March 2026
Despatch Prospectus and SPP Open Date	Thursday, 16 April 2026
SPP Close Date	5.00 pm AEST on Friday, 8 May 2026
Announcement of SPP Results	Before noon (Sydney time) Friday, 15 May 2026
Allotment of SPP Offer Securities	Friday, 15 May 2026

To participate in the SPP Offer, you should pay via BPAY® in accordance with the instructions on your personalised Application Form.

- Eligible Shareholders can download a copy of the Prospectus, the TMD and their personalised application form online at www.investorserve.com.au; or
- contact the Offer Information Line on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) from 8.30am to 5.00pm AEST Monday to Friday to request a copy of the prospectus and their personalised Application Form.

You should be aware that your own financial institution may implement earlier cut-off times with regard to electronic payment, and you should therefore take this into consideration when making payment. It is your responsibility to ensure that funds submitted through BPAY® are received by 5.00 pm AEST on Friday, 8 May 2026, unless the SPP Offer is extended.

Shareholders should read the Prospectus, TMD and Application Form in full prior to making an application for securities under the Plan.

Atomo will not be printing or despatching hard copies of the Prospectus, or TMD except in response to specific requests by an Eligible Shareholder. If you are unable to access the documents online and need to make a request for hard copies to be posted or emailed to you, please contact the Registry on 1300 737 760 (callers within Australia) and +61 2 9290 9600 (callers outside Australia) from 8.15 am to 5.30 pm AEST during the Offer period.

Further information

In accordance with the terms and conditions contained in the Prospectus, the Offer is non-renounceable and securities in Atomo may be issued under the Offer only to the Eligible Shareholder.

In deciding whether to participate in the Offer, you should seek your own independent financial, legal and taxation advice in respect of the Offer. No cooling off regime applies to the acquisition of Shares under the Offer.

On behalf of the Board, I thank you for your continued support of Atomo and I invite you to consider participating in the Offer.

Yours faithfully



Mathew Watkins
Company Secretary
Atomo Diagnostics Limited